Ying Huang

Dr. Ying Huang

College of Pharmacy, Jinan University, Guangzhou 510632, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in ACS Nano
Verified
Journal Article
Closed access
FFFangqin Fu
Fangqin Fu
WWWenhao Wang
Wenhao Wang
LWLinjing Wu
Linjing Wu
WWWenhua Wang
Wenhua Wang
Zhengwei HuangZhengwei Huang
Zhengwei Huang
XPXin Pan
Xin Pan

1 April 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
WWWenhao Wang
Wenhao Wang
Zhengwei HuangZhengwei Huang
Zhengwei Huang
YLYanbei Li
Yanbei Li
WWWenhua Wang
Wenhua Wang
JSJiayu Shi
Jiayu Shi
Chuanbin WuChuanbin Wu
Chuanbin Wu
When nanoparticles were introduced into the biological media, the protein corona would be formed, which endowed the nanoparticles with new bio-identities. Thus, controlling protein corona formation is critical to in vivo therapeutic effect. Controlling the particle size is the most feasible method during design, and the influence of media pH which varies with disease condition is quite important. The impact of particle size and pH on bovine serum albumin (BSA) corona formation of solid lipid nanoparticles (SLNs) was studied here. The BSA corona formation of SLNs with increasing particle size (120–480 nm) in pH 6.0 and 7.4 was investigated. Multiple techniques were employed for visualization study, conformational structure study and mechanism study, etc. “BSA corona-caused aggregation” of SLN2‒3 was revealed in pH 6.0 while the dispersed state of SLNs was maintained in pH 7.4, which significantly affected the secondary structure of BSA and cell uptake of SLNs. The main interaction was driven by van der Waals force plus hydrogen bonding in pH 7.4, while by electrostatic attraction in pH 6.0, and size-dependent adsorption was confirmed. This study provides a systematic insight to the understanding of protein corona formation of SLNs.

22 April 2022 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Wenhao WangWenhao Wang
Wenhao Wang
Zhengwei HuangZhengwei Huang
Zhengwei Huang
Ying HuangYing Huang
Ying Huang
XZXuejuan Zhang
Xuejuan Zhang
JHJiayuan Huang
Jiayuan Huang
XPXin Pan
Xin Pan

20 April 2017 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
JHJiayuan Huang
Jiayuan Huang
TPTingting Peng
Tingting Peng
YLYanrong Li
Yanrong Li
ZZZhengwen Zhan
Zhengwen Zhan
YZYoumei Zeng
Youmei Zeng
CWChuanbin Wu
Chuanbin Wu

18 September 2020 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
CMCheng Ma
Cheng Ma
MWMingjun Wu
Mingjun Wu
WYWeifen Ye
Weifen Ye
Zhengwei HuangZhengwei Huang
Zhengwei Huang
XMXiangyu Ma
Xiangyu Ma
CWChuanbin Wu
Chuanbin Wu

30 October 2019 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
YYYao Yang
Yao Yang
Zhengwei HuangZhengwei Huang
Zhengwei Huang
JLJinyuan Li
Jinyuan Li
ZMZiran Mo
Ziran Mo
Ying HuangYing Huang
Ying Huang
CWChuanbin Wu
Chuanbin Wu